OptimizeRx Expands Investment in Hospitals and Health Systems with Latest Tech and Personnel Adds
08 April 2019 - 2:31PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading digital health messaging
platform for the pharmaceutical industry, announced its latest
platform integration with the health care industry’s leading acute
electronic health record (EHR) systems, including Epic and Cerner.
This latest announcement is a reflection of the company’s continued
investment in hospitals and health systems, also emphasized in the
latest company hiring of Denys Ashby as vice president of Hospitals
& Health Systems.
“At OptimizeRx, we are unwavering in our commitment to bring
affordability and adherence solutions to the industry,” said Miriam
Paramore, president at OptimizeRx. “By linking our platform to the
industry’s leading EHRs, hospitals and health systems across the
country will now have access to critical information – from patient
savings opportunities to medication adherence information – that
empowers the patient with lower cost plus high-touch support
programs. Hospitals and health systems will benefit from reduced
readmissions, increased patient satisfaction, and improved quality
care.”
OptimizeRx’s technical integration with Epic and Cerner enables
healthcare providers to provide patient savings opportunities for
nearly all medications. Research points to improved medication
adherence when patients can identify ways of lowering their
co-payments.
Having accomplished this EHR connectivity, OptimizeRx is further
investing in the hospitals and health systems landscape by adding
Denys Ashby to focus on hospital sales. OptimizeRx expects these
efforts to support its stated goal of an additional 20% reach to
physicians by the end of 2019.
Continued Paramore: “Denys’ experience is going to add
significant value to OptimizeRx’s hospital and health system
strategy. He is a proven leader with more than 25 years of
experience in sales across the health care, pharma, capital,
pharmacy automation, workflow and clinical software markets, and
we’re thrilled to welcome him on board to lead the expansion of our
ecosystem.”
Ashby most recently served as national director of business
development at CaptureRx. He has held previous positions with
McKesson, Cerner and ScriptPro. He earned a degree from the
University of Kansas.
“There is much momentum at OptimizeRx,” said Ashby. “Every
patient will have the opportunity to go home with patient savings
opportunities to better afford, and therefore adhere to, their
medications. I’m excited about how this will shape the care
landscape for the better in the months and years to come and
delighted to join this team.”
For more information on OptimizeRx, please visit
OptimizeRx.com.
About OptimizeRx
OptimizeRx® (NASDAQ: OPRX), a digital health
company, connects pharmaceutical companies to patients
and providers, offering greater affordability, adherence and brand
awareness at the point-of-care. As the nation’s largest
point-of-prescribe promotional platform for the pharmaceutical
industry, OptimizeRx provides a direct channel for pharma
companies to communicate with healthcare providers right within
their workflow and also directly to patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications
platform.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
Communications(Tel) 860-800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024